Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-06-21
2011-06-21
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S094000, C514S118000, C514S385000
Reexamination Certificate
active
07964583
ABSTRACT:
The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formulawherein A+represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
REFERENCES:
patent: 5055459 (1991-10-01), Andersson et al.
patent: 5468499 (1995-11-01), Chan et al.
patent: 2008/0255056 (2008-10-01), Amedio et al.
patent: 51-059886 (1976-05-01), None
patent: WO-00/71134 (2000-11-01), None
patent: WO-01/79158 (2001-10-01), None
patent: WO 2006/047575 (2006-05-01), None
Chemical Abstracts Accession No. 81:37378 & SU 427945 A1 (Institute of Heteroorganic Compounds) May 15, 1994.
Han, S.Y. et al., “Synthesis of17O (and18O) Labelled Isophosphoramide Mustard” Journal of Labelled Compounds and Radiopharmaceuticals 34:(3):247-254 (1994).
Misiura, K et al., Isophosphoramide mustard analogues as prodrugs for anti-cancer gene-directed enzyme-prodrug therapy (GDEPI) Acta Biochimica Polonica 49(1):169-176 (2002).
Zakharov, S. et al. “Catalytic phosphorylation of polyfluoroalkanols. Communication 5. Catalytic phosphorylation of α-polyfluoroalkylbenzyl alcohols with phosphoryl chloride” Bulletin of the Academy of Sciences of the USSR 25(8):1727-31 (1976).
Pohl et al., “D-19575-a Sugar-Linked Isophosphoramide Mustard Derivative Exploiting Transmembrane Glucose Transport,” Cancer Chemotherapy and Pharmacology, 35(5):364-370 (1995).
Wagner, J., “Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized”, Journal of Pharmacokinetics and Biopharmaceutics, 1(2):165-173 (1973).
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002368999, accession No. BRN 2249643, abstract, and Breil, S. et al.: Phosphorus, Sulfur Silicon Relat. Elem., 177(8-9):1939-1940 (2002).
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453066, Database accession No. BRN 6845680, abstract, Shulman-Roskes et al.: J. Labelled Comp. Radiopharm., 34(3):231-238 (1994).
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453067 retrieved from XFIRE, Database accession No. BRN7291472, abstract and Database CA.
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453069, retrieved from XFIRE, Database accession No. BRN 6559377, BRN 6509713, BRN 6503975, abstract.
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453070 retrieved from XFIRE, Database accession No. 9763485, abstract, Misiura, K.: Pharmazie, 59(9):668-672 (2004).
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453071 retrieved from XFIRE, Database accession No. BRN 9261194, BRN 9259456, abstract, Rouvese et al.: Phosphorus, Sulfur, Silicon Rel. Elem., 177(6-7):1735-1738 (2002).
DATABASE Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002453072 retrieved from XFIRE, Database accession No. BRN 8468593, BRN 8458718, abstract, Dirven et al.: Chem. Res. Txicol., 8(7):979-986 (1995).
Database Beilstein [online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002369000, Database accession No. BRN 6835849 abstract, and Shulman-Roskes et al.: J. Labelled Comp. Radiopharm., 34(3):231-238 (1994).
Database Biosis [online], Biosciences Information Service, Philadelphia, PA, US (1994), Shulman-Roskes Ellen M. et al., “Synthesis of 15N labeled isophosphoramide mustard,” XP002369092, Database accession No. PREV199497274456 abstract and Journal of Labelled Compounds and Radiopharmaceuticals, 34(3)231-237 (1994).
Database CA [online] Chemical Abstracts Service, Columbus, OH, US; Millis et al., “Comparison of the Protonation of Isophosphoramide Mustard and Phosphoramide Mustard,” XP002453068, retrieved from STN Database accession No. 1995:592274, abstract.
Boal et al., “Phosphorus-31 NMR Studies of the Kinetics of Bisalkylation by Isophosphoramide Mustard: Comparisons with Phosphoramide Mustard,” J. Med. Chem., 32(8):1768-1773 (1989).
Ludeman et al., “Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of ‘Phenylketophosphamide’ and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide,” J. Med. Chem., 29(5):716-727 (1986).
Millis et al., “Comparison of the Protonation of Isophosphoramide Mustard and Phosphoramide Mustard,” J. Med. Chem., 38(12):2166-2175 (1995).
Rauen et al., “Alkylans-Alkylandum-Reaktionen 2-Chloraethylmin Und Phosphamidverbindungen Als Alkylantien,” Arzneimittel Forschung. Drug Research, ECV Editio Cantor Verlag, Aulendorf, DE, 21(4):518-524 (1971) XP001105865.
Springer et al., “Isophosphoramide Mustard and Its Mechanism of Bisalkylation,” J. Org. Chem., 63(21):7218-7222 (1998).
Voelcker, G., et al., “Structure/activity studies with thiazolidinyl-and perhydrothiazinyl-phosphamide esters,” Journal of Cancer Research and Clinical Oncology, vol. 124(6):197-300 (1998).
Cole et al., “Gas chromatography-electron ionization mass spectrometry and liquid chromatography-electrospray tandem mass spectrometry for determination of impurities in the anti-cancer drug isophosphoramide mustard,” International Journal of Mass Spectrometry, 231:147-155 (2004).
Germann et al., “Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide,” Cancer Chemotherapy and Pharmacology, Springer-Verlag Heidelberg, 55:143-151 (2005). Epub 2004.
Struck et al., “Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide,” Br. J. Cancer, 47:015-026 (1983).
Zheng et al., “Preclinical pharmacokinetics and stability of isophosphoramide mustard,” Cancer Chemother Pharmacol, 33:391-398 (1994).
European Search Report dated Nov. 7, 2007 for EP 05821125.
International Search Report dated Jun. 23, 2006 for PCT/US2005/038523.
Ropes & Gray LLP
Sackey Ebenezer
Wilson James O
Ziopharm Oncology, Inc.
LandOfFree
Salts of isophosphoramide mustard and analogs thereof as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salts of isophosphoramide mustard and analogs thereof as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salts of isophosphoramide mustard and analogs thereof as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696193